Interestingly, in our in vivo studies, we observed lower levels of SAA-3, the equivalent of human C-reactive protein and an important surrogate of CRS in human studies in mice treated with the CD126 targeting construct compared to controls. This evidence concerns the gene IL6R and congenital rubella syndrome.